Abstracts tagged "Innate Immunity Rheumatic Disease"

Abstract Number: 0250 • ACR Convergence 2024
Effectiveness of Tuberculosis Preventive Treatment in Patients with Rheumatic Diseases: A Global Meta-analysis of Cohort Studies
Beiming Wang¹, Shi Chen², Xiaoqing Liu³ and Lifan Zhang³, ¹Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking union medical college hospital, Beijing, China
Background/Purpose: As patients with rheumatic diseases (RDs) growing into a large population globally, concerns continue exist regarding the potential development of tuberculosis (TB) in this…
Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Leonie Middelink¹, Annemarie Kip², Maarten van der Linden³, Sangeeta Kumari², Stephanie van Dalen², Josephine Stein⁴, Tirza Bruurmijn², Martyn Foster⁵, Peter van Zandvoort², Patrick Round², Eric Meldrum², Helmuth van Es² and Renato Chirivi², ¹Citryll, Oss, Noord-Brabant, Netherlands, ²Citryll BV, Oss, Noord-Brabant, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴Citryll BV, Oss, Noord-Holland, Netherlands, ⁵Experimental Pathology Consultancy, Benfleet, United Kingdom
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…
Abstract Number: 0933 • ACR Convergence 2024
NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
Abstract Number: 1537 • ACR Convergence 2024
Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Kelly A. Pike¹, Nadine Fradet¹, Samuel Gaudreault¹, Alexander M Skeldon², Ramsay E. Beveridge², Patrick Cyr², Nicolas Sgarioto², Philippe Le Gros³, Eleftheria Seliniotakis², Valerie Dumais², Jacklyn Smith², James I.P Stewart², Mehrnaz Gharaee-Kermani⁴, Michelle J Kahlenberg⁴ and Michael A. Crackower², ¹Ventus Therapeutics, Saint-Laurent, QC, Canada, ²Ventus Therapeutics, Saint-Laurent, Canada, ³Ventus Therapeutics, Montreal, QC, Canada, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Cyclic GMP-AMP synthase (cGAS) is a nucleic acid sensor that plays a central role in anti-viral responses. Following the detection of intracellular double-stranded DNA,…
Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka¹, Atsushi Kumanogoh², Tatsuya Atsumi³, Tomonori Ishii⁴, Fumitoshi Tago⁵, Mari Aoki⁵, Shintaro Yamamuro⁵, Keisuke Sakayori⁵, Kentaro Takahashi⁵ and Shizuo Akira⁶, ¹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²Osaka University, Osaka, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁵Eisai Company, Ltd., Tokyo, Japan, ⁶Osaka University Immunology Frontier Research Center, Osaka, Japan
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…
Abstract Number: 2369 • ACR Convergence 2023
Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients
Hadijat Makinde¹, Matthew Dapas², Salina Dominguez², Tyler Therron¹, Miranda Gurra¹, Mary Karns³, Kathleen Aren³, Alexandra Soriano², Lutfiyya Muhammad⁴, Carla Cuda¹, Dustin Carlson¹, Jane Dematte⁵, Darren Brenner¹, John Pandolfino⁶, Harris Perlman¹, Deborah Winter⁷ and Marie-Pier Tetreault¹, ¹Northwestern University, Chicago, IL, ²Northwestern University FSM Division of Rheumatology, Chicago, IL, ³Northwestern University Division of Rheumatology, Chicago, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Elmhurst, IL, ⁶Northwestern University, Feinberg School of Medicine, Wilmette, IL, ⁷Northwestern University, Skokie, IL
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with Gastroesophageal Reflux Disease (GERD),…
Abstract Number: 0052 • ACR Convergence 2023
Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes
Keiko Yoshimoto¹, Yumi Ikeda¹, Katsuya Suzuki², Hiroyuki Fukui¹, Kotaro Matsumoto¹, Masaru Takeshita¹, Tsutomu Takeuchi³ and Yuko Kaneko⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²Keio University, Shinjuku, Japan, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Toll-like receptors (TLRs) play a pivotal role in innate immune system and chronic inﬂammation in autoimmune diseases. It has been reported that signaling pathways…
Abstract Number: 0061 • ACR Convergence 2023
Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases
Marta Wlodarska¹, Chad Van Huis², Florian Hoss³, Rosana Meyer¹, Xiaokang Lu², Dominik Koelmel², Brian Sanchez², Chuck Lesch², Alissa Telling², Martin Minns¹, Nneka Mbah², Isabelle Lacan¹, Robert Aversa¹, Charles Lesburg¹, Carmen Yu², Stephen Soisson¹, Natalie Dales¹, Darryl Patrick¹, Anthony Opipari², Shifeng Pan⁴ and Luigi Franchi², ¹Odyssey Therapeutics, Boston, MA, ²Odyssey Therapeutics, Ann Arbor, MI, ³Odyssey Therapeutics, Frankfurt, Germany, ⁴Odyssey Therapeutics, San Diego, CA
Background/Purpose: Receptor interacting protein kinase 2 (RIPK2) is a key signaling node for inflammation caused by peptidoglycan (PGN). In the intestine, RIPK2 integrates signaling originating…
Abstract Number: 0275 • ACR Convergence 2023
No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry
Jasmin B. Kuemmerle-Deschner¹, Joerg Henes², Birgit Kortus-Goetze³, Prasad T. Oommen⁴, Anne Pankow⁵, Tilmann Kallinich⁶, Tobias Krickau⁷, Catharina Schuetz⁸, Gerd Horneff⁹, Ivan Foeldvari¹⁰, Juergen Rech¹¹, Frank Weller-Heinemann¹², Ales Janda¹³, Markus Hufnagel¹⁴, Florian M. Meier¹⁵, Frank Dressler¹⁶, Michael Borte¹⁷, Ioana Andreica¹⁸, Peter Wasiliew¹⁹, Michael Fiene²⁰, Daniel Windschall²¹, Martin Krusche²², Tania Kuempfel²³, Julia Weber-Arden²⁴ and Norbert Blank²⁵, ¹med.uni-tuebingen, Tübingen, Germany, ²University Hospital Tuebingen, Tuebingen, Germany, ³Department of Internal Medicine, Division of Nephrology,University Hospital of Giessen and Marburg, Marburg, Germany, ⁴Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health,Medical Faculty Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁵Department of Rheumatology and Clinical Immunology,Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Nuremberg, Germany, ⁷Pediatrics, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen, Germany, ⁸Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus,Technische Universität Dresden, Dresden, Germany, ⁹Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹⁰Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ¹¹University Clinic Erlangen, Erlangen, Germany, ¹²Division of Pediatric Rheumatology, Prof. Hess Children's Hospital, Bremen, Bremen, Germany, ¹³Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany, ¹⁴Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁵Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, Frankfurt am Main, Germany, ¹⁶Department of Paediatric Pneumology, Allergology and Neonatology, Children's Hospital, Hannover Medical School, Hannover, Germany, ¹⁷Hospital for Children & Adolescents, St. Georg Hospital, Leipzig, Germany, ¹⁸Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁹Division of Pediatric Rheumatology and autoinflammation reference center Tuebingen, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ²⁰Rheumatology Center Greifswald, Greifswald, Germany, ²¹Clinic of Paediatric and Adolescent Rheumatology, St. Josef-Stift Sendenhorst, Northwest German Center for Rheumatology, Sendenhorst, Germany, ²²UKE, Hamburg, Germany, ²³Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universität München, Muenchen, Germany, ²⁴Novartis Innovative Medicines, Nuernberg, Germany, ²⁵University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Autoinflammatory diseases (AID) have been treated safely and effectively with the interleukin-1β inhibitor canakinumab (CAN) in controlled trials and routine clinical practice. The most…
Abstract Number: 0276 • ACR Convergence 2023
Disease Control in Patients with Monogenetic Autoinflammatory Diseases Under Canakinumab Treatment – Comparison of 30 Months Interim Data from the RELIANCE Registry
Ivan Foeldvari¹, Tilmann Kallinich², Norbert Blank³, Joerg Henes⁴, Birgit Kortus-Goetze⁵, Prasad T. Oommen⁶, Anne Pankow⁷, Tobias Krickau⁸, Catharina Schuetz⁹, Gerd Horneff¹⁰, Juergen Rech¹¹, Frank Weller-Heinemann¹², Ales Janda¹³, Markus Hufnagel¹⁴, Florian M. Meier¹⁵, Frank Dressler¹⁶, Michael Borte¹⁷, Ioana Andreica¹⁸, Peter Wasiliew¹⁹, Michael Fiene²⁰, Daniel Windschall²¹, Martin Krusche²², Tania Kuempfel²³, Julia Weber-Arden²⁴ and Jasmin B. Kuemmerle-Deschner²⁵, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité Universitätsmedizin Berlin, Nuremberg, Germany, ³University Hospital Heidelberg, Heidelberg, Germany, ⁴University Hospital Tuebingen, Tuebingen, Germany, ⁵Department of Internal Medicine, Division of Nephrology,University Hospital of Giessen and Marburg, Marburg, Germany, ⁶Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health,Medical Faculty Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁷Department of Rheumatology and Clinical Immunology,Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Pediatrics, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen, Germany, ⁹Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus,Technische Universität Dresden, Dresden, Germany, ¹⁰Asklepios Klinik Sankt Augustin GmbH, Bonn, Germany, ¹¹University Clinic Erlangen, Erlangen, Germany, ¹²Division of Pediatric Rheumatology, Prof. Hess Children's Hospital, Bremen, Bremen, Germany, ¹³Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany, ¹⁴Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹⁵Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, Frankfurt am Main, Germany, ¹⁶Department of Paediatric Pneumology, Allergology and Neonatology, Children's Hospital, Hannover Medical School, Hannover, Germany, ¹⁷Hospital for Children & Adolescents, St. Georg Hospital, Leipzig, Germany, ¹⁸Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ¹⁹Division of Pediatric Rheumatology and autoinflammation reference center Tuebingen, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ²⁰Rheumatology Center Greifswald, Greifswald, Germany, ²¹Clinic of Paediatric and Adolescent Rheumatology, St. Josef-Stift Sendenhorst, Northwest German Center for Rheumatology, Sendenhorst, Germany, ²²UKE, Hamburg, Germany, ²³Institute of Clinical Neuroimmunology, Biomedical Center and University Hospital, Ludwig-Maximilians Universität München, Muenchen, Germany, ²⁴Novartis Innovative Medicines, Nuernberg, Germany, ²⁵med.uni-tuebingen, Tübingen, Germany
Background/Purpose: Treatment of autoinflammatory periodic diseases (AID) with the interleukin-1β inhibitor canakinumab (CAN) has been shown to be safe and effective in controlled trials and…
Abstract Number: 0724 • ACR Convergence 2023
Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model
Richard Bell, Ewurama Cann, Chao Yang, Accelerating Medicine Partnership Rheumatoid Arthritis, Amit Lakhanpal, Laura Donlin and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Macrophages (MФ) play a key pathogenic role in Rheumatoid Arthritis (RA), a disease that exhibits female sex bias. Recent work using scRNAseq has defined…
Abstract Number: 0757 • ACR Convergence 2023
Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals
Pierre-Antoine Juge¹, Gregory McDermott², Keigo Hayashi², Jing Cui³, Clémence David-Gabarre⁴, Marie-Louis Frémond⁴, Holly Wobma⁵, Soumya Raychaudhuri², Elizabeth Karlson², Philippe Dieudé⁶ and Jeffrey Sparks⁷, ¹Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Imagine, Paris, France, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, INSERM UMR1152, University de Paris Cité, Department of Rheumatology, Paris, France, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: COPA syndrome is a rare, severe monogenic autoinflammatory/autoimmune disorder with variable penetrance, most commonly affecting the lungs and joints. It is caused by dominant…
Abstract Number: 0797 • ACR Convergence 2023
Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis
Agnieszka Lastowska¹, Charlotte E. van der Plas¹, Anders Nguyen¹, Symeon Kourmoulakis¹, Miriam Bollmann¹ and Mattias N.D Svensson², ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid cells (ILCs) are innate counterparts to T-cells that, based on their functional phenotype, can be divided into three subpopulations called Group 1…
Abstract Number: 0838 • ACR Convergence 2023
Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections
Russell Ross¹, Vibeke Strand², Roel Querubin³, John Goldman⁴, Richard Leff⁵, Alexis Melson¹, Pei-Ling Roerig⁶ and Alan Smith⁷, ¹Sorrento Therapeutics, Atlanta, GA, ²Stanford University, Portola Valley, CA, ³Marietta Rheumatology Associates, Marietta, GA, ⁴Northside Hospital, Atlanta, GA, ⁵Kezar Life Sciences, Chadds Ford, PA, ⁶4P Therapeutics, Orlando, FL, ⁷4P Therapeutics, Atlanta, GA
Background/Purpose: The lymphatic system serves as a conduit for transporting immune cells and inflammatory molecules present in arthritic joints to lymph nodes (LN), playing a…
Abstract Number: 1712 • ACR Convergence 2023
Identification and Functional Characterization of Eight CANDLE/PRAAS Causing Proteasome Variants in Five Unrelated Patients
Adriana Almeida de Jesus¹, Jonas J. Papendorf², Frederic Ebstein³, Sara Alehashemi⁴, Daniela Pioto⁵, Anna Kozlova⁶, Maria Teresa TErreri⁷, Anna Shcherbina⁶, Andre Rastegar⁸, Marta Rodrigues⁹, Renan Pereira¹⁰, Sophia Park¹¹, Bin Lin¹², Kat Uss¹¹, Ana Flavia da Silva Pina⁵, FLAVIO SZTAJNBOK¹³, Sofia Torreggiani¹⁴, Jennifer Stoddard¹⁵, Julie Niemela¹⁵, Sergio Rosenzweig¹⁵, Adriana Fonseca¹⁶, Marietta De Guzman¹⁷, Nicole Micheloni⁵, Melissa Fraga⁵, Sandro Perazzio¹⁸, Raphaela Goldbach-Mansky¹⁹ and Elke Krueger², ¹NIAID, NIH, Bethesda, MD, ²Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, ³Nantes Université, Nantes, France, ⁴NIH/NIAID/TADS, Clarksville, MD, ⁵Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ⁶Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, ⁷UNIFESP, São Paulo, Brazil, ⁸NIH, Bethesda, MD, ⁹Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, ¹⁰Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹¹Translational Autoinflammatory Diseases Section, LCIM, NIAID, NIH, Bethesda, MD, ¹²Translational Autoinflammatory Diseases Section l LCIM, NIAID, NIH, Bethesda, MD, ¹³UFRJ/UERJ, São Paulo, Brazil, ¹⁴University of Maryland Baltimore, Baltimore, MD, ¹⁵Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD, ¹⁶Instituto de Puericultura e Pediatria Martagao Gesteira / Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Baylor College of Medicine, Houston, TX, ¹⁸Universidade de Sao Paulo (Unifesp); Universidade de São Paulo (USP); Fleury Laboratories, São Paulo, Brazil, ¹⁹NIH/NIAID, Potomac, MD
Background/Purpose: Mutations in genes coding for 20S proteasome subunits or proteasome assembly helpers cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE) or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].